Newer Treatment Modalities in Urticaria
Meghana Pendam *
Department of DVL, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences(Deemed to be university), Wardha, Maharashtra, 442001, India.
Bhushan Madke
Department of DVL, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences(Deemed to be university), Wardha, Maharashtra, 442001, India.
*Author to whom correspondence should be addressed.
Abstract
Wheals (hives), angioedema, or both are symptoms of urticaria, a chronic clinical disorder. Urticaria has a complicated pathogenesis, as well as a large disease burden, a negative effect on health-care expenditures and quality of living. Urticaria could also be a chronic condition that affects up to 1% of the general population at some stage in their lives and can drastically impair quality life. The use of second-generation, non-sedating antihistamines has replaced antihistamines to use as the first-line therapy. However, urticaria can be difficult to manage in some cases; in these cases, alternate treatment approaches must be considered. This article reviews antihistamines, leukotriene antagonists, anti-inflammatory drugs, biologicals, subcutaneous autologous serum therapy, doxepin, cyclosporine ,tranexamic acid and other newer treatment modalities.
Keywords: Urticaria, wheals, histamine